Health and Me on MSN
FDA approves targeted cancer drug as first-line treatment for CLL that cuts progression risk by 80%
The US Food and Drug Administration (FDA) recently approved pirtobrutinib for people with previously untreated chronic ...
Everyday Health on MSN
CLL and swollen lymph nodes: What you need to know
What causes enlarged lymph nodes in CLL and when to call your doctor.
CLL care shifts to targeted combinations, confronting BTK resistance with next-gen inhibitors, degraders, and BCL2 drugs, ...
Treatments for the most common form of adult leukemia, chronic lymphocytic leukemia (CLL), have changed dramatically over the ...
FDA expanded pirtobrutinib into frontline CLL/SLL for patients without del(17p), establishing a noncovalent BTK inhibitor option earlier in the treatment sequence. BRUIN CLL-313 demonstrated ...
Eli Lilly’s Jaypirca, the first noncovalent BTK inhibitor, has won FDA approval for the first-line treatment of chronic ...
The FDA has approved pirtobrutinib (Jaypirca) monotherapy as a treatment for adults with previously untreated chronic ...
The U.S. Food and Drug Administration (FDA) has expanded the approved indication for pirtobrutinib (Jaypirca) to include the ...
Oncology clinicians gathered to review relapsed CLL care options, CAR T-cell trial updates, and advanced practice provider roles. On Sept. 28, 2026, oncology healthcare professionals convened at the ...
Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved an additional indication for Jaypirca (pirtobrutinib, 100 mg & 50 mg tablets), a ...
FDA expands pirtobrutinib into first-line CLL/SLL for adults without 17p deletion, delivering major PFS gains versus ...
The FDA expanded the approval of pirtobrutinib to include initial treatment of adults with chronic lymphocytic leukemia or small lymphocytic leukemia with no known 17p deletion. Pirtobrutinib ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results